During the 24-month follow-up, 51.4% of the initiators of other drugs purchased ACE inhibitors/ARB inhibitors, 33.4% beta blockers, 17.9% diabetes drugs, and 17.3% nitrates (S1 Table). The gene discussed is ACE; the disease is diabetes mellitus.